Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Novatio Ventures is a venture capital firm dedicated to the commercialization of high-potential life science innovations. Founded by Peng Fu, the firm operates from Toronto, Boston, and Hong Kong. It targets early-stage innovations that are nearing preclinical proof-of-concept or validation, providing seed funding to promising startups. The organization collaborates closely with inventors, entrepreneurs, and institutions to develop and implement effective commercialization strategies.
As of now, Novatio Ventures has established a strong presence in the life sciences sector, focusing on biotech and healthcare innovations. The firm leverages its global industry network and collective experience to facilitate early exits that generate financial returns while mitigating risks. This approach positions Novatio Ventures as a key player in the life sciences investment landscape.
Novatio Ventures invests primarily in early-stage life science innovations, particularly those emerging from Canada, the U.S., China, South Korea, and other markets. The firm specializes in biotech and healthcare sectors, focusing on innovations that are nearing preclinical proof-of-concept or validation. Their investment strategy is designed to leverage a global network to achieve early exits while generating financial returns and mitigating risks.
Investment stages include pre-seed and seed, with check sizes tailored to the specific needs of the startups. Novatio Ventures seeks to partner with founders who demonstrate a strong vision and capability in their respective fields. The firm values collaboration and actively engages with its portfolio companies to enhance their commercialization strategies.
Novatio Ventures has a notable portfolio that includes several promising companies in the life sciences sector:
These companies exemplify Novatio Ventures' commitment to supporting early-stage innovations that have the potential to make significant impacts in healthcare and biotechnology.
Peng Fu, MSc, JD - General Partner. Peng has extensive experience in venture capital and law, focusing on life sciences investments.
Chris Kim, PhD, MBA - Managing Director. Chris brings a strong background in biotech and healthcare, with a focus on commercialization strategies.
Sandy Der, PhD - Partner. Sandy co-founded Immvue Therapeutics and has expertise in immuno-oncology.
Ben Walker, MBA - Partner. Ben has a background in business development and investment management, contributing to the firm's strategic direction.
To pitch to Novatio Ventures, founders should visit their website at Novatio Ventures. It is important to include a comprehensive business plan and details about the innovation's current stage. Response times may vary, but founders can expect to hear back within a few weeks.
As of October 2023, Novatio Ventures continues to expand its portfolio in the life sciences sector, focusing on early-stage innovations. The firm has made significant investments in companies like 3io Therapeutics and Precision Proteomics, enhancing its presence in the biotech landscape.
Recent activities include ongoing collaborations with inventors and institutions to develop commercialization strategies for their portfolio companies. The firm remains committed to achieving early exits that generate financial returns while mitigating risks.
What are Novatio Ventures' investment criteria?
Novatio Ventures focuses on early-stage life science innovations, particularly those nearing preclinical proof-of-concept or validation. They invest in biotech and healthcare sectors, primarily targeting companies from Canada, the U.S., China, and South Korea.
How can I apply or pitch to Novatio Ventures?
Founders can submit their pitches through the official website at Novatio Ventures. It is recommended to include a detailed business plan and information about the innovation's stage of development.
What makes Novatio Ventures different from other investors?
Novatio Ventures emphasizes collaboration with inventors and institutions to develop commercialization strategies. Their focus on early-stage life sciences and their global network allows them to facilitate early exits while mitigating risks.
What is the geographic scope of Novatio Ventures?
The firm primarily invests in North America and Asia, specifically targeting innovations from Canada, the U.S., China, and South Korea.
What is the typical check size for investments?
Novatio Ventures invests at the pre-seed and seed stages, with check sizes tailored to the specific needs of the startups they support.
What kind of post-investment involvement does Novatio Ventures have?
Novatio Ventures actively collaborates with portfolio companies to enhance their commercialization strategies, providing mentorship and access to their global network.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.